Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
March 08, 2022 02:00 ET
|
INVENTIVA
FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023 ...
Global Artificial Intelligence (AI) in Drug Discovery Market ($4197.5 Mn by 2028) Growth Forecast at 41.5% CAGR During 2022 to 2028 COVID Impact and Global Analysis by Vantage Market Research
March 03, 2022 04:49 ET
|
Vantage Market Research
WASHINGTON, March 03, 2022 (GLOBE NEWSWIRE) -- The Global Artificial Intelligence in Drug Discovery Market size is expected to reach USD 4,197.5 Million by 2028, exhibiting a Compound Annual Growth...
BioRestorative Therapies Announces Closing of $23 Million Public Offering
November 09, 2021 14:20 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced...
Wereldhave commits to setting Science-Based Targets
March 13, 2020 03:29 ET
|
Wereldhave N.V.
Press release | Wereldhave commits to setting Science-Based TargetsWereldhave is pleased to announce it has committed itself to reduce carbon emissions to a level in line with what climate science...
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
January 21, 2020 09:15 ET
|
Ritter Pharmaceuticals, Inc.
Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE...
BioRestorative Therapies Receives Patent in Israel For Its Metabolic Program
December 12, 2019 09:45 ET
|
BioRestorative Therapies, Inc.
MELVILLE, N.Y., Dec. 12, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today...
BioRestorative Therapies Receives A Second Patent in Australia For Its Metabolic Program
October 23, 2019 09:45 ET
|
BioRestorative Therapies, Inc.
MELVILLE, N.Y., Oct. 23, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the...
Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives
October 07, 2019 09:00 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that...
Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
December 04, 2018 08:30 ET
|
Ritter Pharmaceuticals, Inc.
Full Enrollment on Target for Q2 2019 with Data Readout Expected in the Second Half of 2019 LOS ANGELES, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter...
Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants
November 06, 2018 07:00 ET
|
Ritter Pharmaceuticals, Inc.
Proceeds Expected to be Sufficient to Fund Company’s Liberatus Phase 3 Clinical Trial for RP-G28 for Lactose Intolerance Through Announcement of Top-Line Data Anticipated in the Second Half of 2019...